O	0	3	The
O	4	9	Kampo
O	10	18	medicine
B-intervention	19	32	Goshajinkigan
O	33	41	prevents
B-condition	42	52	neuropathy
O	53	55	in
B-eligibility	56	62	breast
I-eligibility	63	69	cancer
I-eligibility	70	78	patients
I-eligibility	79	86	treated
I-eligibility	87	91	with
I-eligibility	92	101	docetaxel
O	101	102	.

O	103	116	Goshajinkigan
O	117	118	(
O	118	121	GJG
O	121	122	)
O	123	125	is
O	126	130	used
O	131	134	for
O	135	138	the
O	139	148	treatment
O	149	151	of
O	152	159	several
O	160	172	neurological
O	173	181	symptoms
O	181	182	.

O	183	185	We
O	186	198	investigated
O	199	202	the
O	203	211	efficacy
O	212	214	of
O	215	218	GJG
O	219	222	and
O	223	234	mecobalamin
O	235	236	(
O	236	239	B12
O	239	240	)
O	241	248	against
O	249	262	neurotoxicity
O	263	273	associated
O	274	278	with
O	279	288	docetaxel
O	289	290	(
O	290	293	DOC
O	293	294	)
O	295	297	in
O	298	304	breast
O	305	311	cancer
O	312	320	patients
O	320	321	.

B-total-participants	322	327	Sixty
O	328	334	breast
O	335	341	cancer
O	342	350	patients
O	351	355	were
O	356	363	treated
O	364	368	with
O	369	372	DOC
O	372	373	.

B-intervention-participants	374	380	Thirty
I-intervention-participants	380	381	-
I-intervention-participants	381	386	three
O	387	395	patients
O	396	397	(
O	397	400	GJG
O	401	406	group
O	406	407	)
O	408	416	received
O	417	421	oral
O	422	436	administration
O	437	439	of
O	440	441	7
O	441	442	.
O	442	443	5
O	444	445	g
O	445	446	/
O	446	449	day
O	450	453	GJG
O	454	457	and
B-control-participants	458	460	27
O	461	469	patients
O	470	471	(
B-control	471	474	B12
I-control	475	480	group
O	480	481	)
O	482	490	received
O	491	495	oral
O	496	510	administration
O	511	513	of
O	514	518	1500
O	519	520	μ
O	520	521	g
O	521	522	/
O	522	525	day
O	526	529	B12
O	529	530	.

O	531	541	Neuropathy
O	542	545	was
O	546	555	evaluated
O	556	565	according
O	566	568	to
O	569	572	DEB
O	572	573	-
O	573	576	NTC
O	577	578	(
O	578	591	Neurotoxicity
O	592	600	Criteria
O	601	603	of
O	604	614	Debiopharm
O	614	615	)
O	615	616	,
O	617	623	Common
O	624	635	Terminology
O	636	644	Criteria
O	645	648	for
O	649	656	Adverse
O	657	663	Events
O	664	665	(
O	665	668	NCI
O	668	669	-
O	669	672	CTC
O	672	673	)
O	674	677	ver
O	677	678	.
O	678	679	3
O	679	680	.
O	680	681	0
O	681	682	,
O	683	686	and
O	687	688	a
O	689	695	visual
O	696	704	analogue
O	705	710	scale
O	711	712	(
O	712	715	VAS
O	715	716	)
O	716	717	.

O	718	722	This
O	723	728	study
O	729	737	employed
O	738	739	a
O	740	750	randomized
O	751	755	open
O	756	762	design
O	762	763	.

O	764	767	The
B-outcome	768	777	incidence
I-outcome	778	780	of
I-outcome	781	791	neuropathy
O	792	795	was
B-iv-bin-percent	796	798	39
I-iv-bin-percent	798	799	.
I-iv-bin-percent	799	800	3
I-iv-bin-percent	800	801	%
O	802	804	in
O	805	808	the
O	809	812	GJG
O	813	818	group
O	818	819	,
O	820	823	and
B-cv-bin-percent	824	826	88
I-cv-bin-percent	826	827	.
I-cv-bin-percent	827	828	9
I-cv-bin-percent	828	829	%
O	830	832	in
O	833	836	the
O	837	840	B12
O	841	846	group
O	847	848	(
O	848	849	p
O	849	850	<
O	850	851	0
O	851	852	.
O	852	854	01
O	854	855	)
O	855	856	.

O	857	859	In
O	860	863	the
O	864	867	GJG
O	868	873	group
O	873	874	,
B-outcome	875	880	grade
I-outcome	881	882	1
I-outcome	883	886	DEB
I-outcome	886	887	-
I-outcome	887	890	NTC
O	891	894	was
O	895	903	observed
O	904	906	in
B-iv-bin-abs	907	908	2
O	909	914	cases
O	914	915	,
B-outcome	916	921	grade
I-outcome	922	923	2
O	924	926	in
B-iv-bin-abs	927	928	5
O	929	934	cases
O	935	938	and
B-outcome	939	944	grade
I-outcome	945	946	3
O	947	949	in
B-iv-bin-abs	950	951	5
O	952	957	cases
O	957	958	.

B-outcome	959	964	Grade
I-outcome	965	966	1
I-outcome	967	970	NCI
I-outcome	970	971	-
I-outcome	971	974	CTC
O	975	978	was
O	979	987	observed
O	988	990	in
B-iv-bin-abs	991	992	7
O	993	998	cases
O	998	999	,
B-outcome	1000	1005	grade
I-outcome	1006	1007	2
O	1008	1010	in
B-iv-bin-abs	1011	1012	6
O	1013	1018	cases
O	1018	1019	,
O	1020	1023	and
B-outcome	1024	1027	VAS
O	1028	1031	was
B-iv-cont-mean	1032	1033	2
I-iv-cont-mean	1033	1034	.
I-iv-cont-mean	1034	1035	7
O	1036	1037	±
B-iv-cont-sd	1038	1039	2
I-iv-cont-sd	1039	1040	.
I-iv-cont-sd	1040	1041	2
O	1041	1042	.

O	1043	1045	In
O	1046	1049	the
O	1050	1053	B12
O	1054	1059	group
O	1059	1060	,
B-outcome	1061	1067	grades
I-outcome	1068	1069	1
I-outcome	1069	1070	,
I-outcome	1071	1072	2
I-outcome	1073	1076	and
I-outcome	1077	1078	3
I-outcome	1079	1082	DEB
I-outcome	1082	1083	-
I-outcome	1083	1086	NTC
O	1087	1091	were
O	1092	1100	observed
O	1101	1103	in
B-cv-bin-abs	1104	1107	one
O	1108	1112	case
O	1112	1113	,
B-cv-bin-abs	1114	1116	12
O	1117	1122	cases
O	1123	1126	and
B-cv-bin-abs	1127	1129	12
O	1130	1135	cases
O	1135	1136	,
O	1137	1149	respectively
O	1149	1150	;
O	1151	1154	and
B-outcome	1155	1161	grades
I-outcome	1162	1163	1
I-outcome	1163	1164	,
I-outcome	1165	1166	2
I-outcome	1167	1170	and
I-outcome	1171	1172	3
I-outcome	1173	1176	NCI
I-outcome	1176	1177	-
I-outcome	1177	1180	CTC
O	1181	1185	were
O	1186	1194	observed
O	1195	1197	in
B-cv-bin-abs	1198	1200	11
O	1201	1206	cases
O	1206	1207	,
B-cv-bin-abs	1208	1210	12
O	1211	1216	cases
O	1217	1220	and
B-cv-bin-abs	1221	1224	one
O	1225	1229	case
O	1229	1230	,
O	1231	1234	and
B-outcome	1235	1238	VAS
O	1239	1242	was
B-cv-cont-mean	1243	1244	4
I-cv-cont-mean	1244	1245	.
I-cv-cont-mean	1245	1246	9
O	1247	1248	±
B-cv-cont-sd	1249	1250	2
I-cv-cont-sd	1250	1251	.
I-cv-cont-sd	1251	1252	4
O	1252	1253	.

O	1254	1265	Concomitant
O	1266	1280	administration
O	1281	1283	of
O	1284	1287	GJG
O	1288	1290	is
O	1291	1297	useful
O	1298	1300	in
O	1301	1311	preventing
O	1312	1322	neuropathy
O	1323	1325	in
O	1326	1332	breast
O	1333	1339	cancer
O	1340	1348	patients
O	1349	1356	treated
O	1357	1361	with
O	1362	1363	a
O	1364	1367	DOC
O	1368	1375	regimen
O	1375	1376	.
